Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

f clinical trials, and the potential therapeutic and commercial potential, of LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... DALLAS , March 31, 2015 ... H1 2015" therapeutic market research report of 68 ... its online business intelligence library. The ... information on the therapeutic development for Pemphigus ... therapeutics assessment by drug target, mechanism of action ...
(Date:3/31/2015)... N.C. , March 31, 2015  Dr. Renu ... be attending the World Orphan Drug Congress in April to ... regulatory approval process and orphan drugs below: ... has recommended to the Ministry of Health that if a ... marketing authorization can be obtained in India ...
(Date:3/31/2015)... March 31, 2015   Halyard Health (NYSE: ... it was awarded a new purchasing agreement with ... Effective March 1, 2015, Halyard,s standard and ASTM-rated ... lining, will be available to HealthTrust members made up ... ambulatory surgery centers, physician practices and alternate care facilities. ...
Breaking Medicine Technology:Pemphigus Therapeutic Development and Pipeline Review H1 2015 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 4Max Neeman to Discuss India's Orphan Drug Regulations at WOD 2015 2Halyard Health Signs First GPO Contracts As Independent Company 2Halyard Health Signs First GPO Contracts As Independent Company 3
... - New Platform May Provide Solutions ... Alloksys Life Sciences BV (Bunnik, The Netherlands), ... announce the start of Theraptech, a 2.4 million Euro ... Program.,The major objective of the Theraptech project is to ...
... CHICAGO, March 2 The Society of Gynecologic Oncologists ... (ACOG) have jointly developed a breast disease fellowship training ... of $75,000 from ACOG, the program provides support for ... in the care and treatment of breast cancer and ...
Cached Medicine Technology:Drug Development Program Started Based on CAP(R) Human Cell Line 2Drug Development Program Started Based on CAP(R) Human Cell Line 3SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists 2SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists 3
(Date:3/31/2015)... 2015 Dr. St. Ledger recently returned from ... Dental Education. Here, he participated in the Worn Dentition ... a greater predictability in cases of severely worn teeth, as ... wear, and the correlation to GERD and Sleep Apnea. ... Spear Education. After the workshop he attended, he mentored ...
(Date:3/31/2015)... La Mirada, CA (PRWEB) March 31, 2015 ... now treating hip injuries at all of their clinics. ... injuries or disorders. , For athletes with hip ... specialists ready to assess and treat the symptoms and ... athletes to provide minimally-invasive care and prevent future damage, ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Beckman Coulter is ... new USP 787: “Subvisible Particulate Matter in Therapeutic Protein Injections”,” ... the new demands in counting particles in liquids, with a ... The webinar is free to attend and will be broadcast ... recently posted a new test for protein-based materials, known as ...
(Date:3/31/2015)... 31, 2015 Indosoft, Inc., developers of ... the availability of SIP over TCP configuration for all SIP ... offering a full contact center ACD (Automatic Call ... Adding SIP over TCP support to all SIP devices gives ... The history of Voice over IP (VoIP) has primarily involved ...
(Date:3/31/2015)... 2015 Greenfield Senior continues to ... LLC ("Care") a seniors housing-focused real estate investment ... announces today, their acquisition of six senior housing ... million. Concurrent with the acquisition, Care will master ... Living ("Greenfield"). Pursuant to the lease, Care will ...
Breaking Medicine News(10 mins):Health News:The dentists at Upper Montclair Dental Associates are happy to announce exciting new happenings at their practice. 2Health News:Healthpointe Now Treating Hip Dislocations, Hip Fractures, Hip Bursitis, and Hip Strains at Locations in Southern California 2Health News:Beckman Coulter Webinar Series Presents Insight into New Demands in Counting Particles in Liquids 2Health News:Beckman Coulter Webinar Series Presents Insight into New Demands in Counting Particles in Liquids 3Health News:Indosoft extends SIP over TCP support to User Extensions in its Q-Suite 5.9 Call Center Software 2Health News:Greenfield Senior Living Inc. Enters Lease Transaction with Care Investment Trust LLC 2Health News:Greenfield Senior Living Inc. Enters Lease Transaction with Care Investment Trust LLC 3
... News) -- People who have dealings with the criminal justice system ... been found guilty or spent time in prison, a new study ... Denmark who died of suicide between 1981 and 2006 and compared ... population. The study found that 34.8 percent of men who ...
... - So-called barrier sites -- the skin, gut, lung ... viruses, bacteria, and parasites. Understanding how the immune system ... such inflammatory diseases as asthma, psoriasis, IBD, and food ... David Artis, PhD, professor of Microbiology and ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... and introduced to solid foods before they were 4 months ... 3, researchers report. The timing of solid foods didn,t ... breast-fed. But among children who were never breast-fed -- or ...
... Despite decades of research and billions of dollars, cancer ... evade both the body,s defenses and medical intervention. Now ... explanation. "Cancer is not a random bunch of ... response to stress, honed by a long period of ...
... Church of Sweden decided to introduce a special blessing ... Church making a distinction between genuine homosexuality and promiscuous ... by a new thesis in religious studies at the ... values between opponents and supporters of the decision. ...
... used by statisticians to analyze data is helping Houston ... and Parkinson,s diseases and stroke. Researchers at Rice ... at Houston (UTHealth) reported today in the journal ... energy transfer (FRET) techniques combined with wavelet transforms have ...
Cached Medicine News:Health News:Brushes With the Law Raise Suicide Risk, Study Shows 2Health News:Giving Baby Solid Foods Too Early Linked to Obesity Later 2Health News:Giving Baby Solid Foods Too Early Linked to Obesity Later 3Health News:Conceptualizing cancer cells as ancient 'toolkit' 2Health News:Supporters and opponents of a special blessing for homosexuals share many values 2Health News:Researchers get a grip on nervous system's receptors 2Health News:Researchers get a grip on nervous system's receptors 3
... Cardiology Hemo is a comprehensive hemodynamic ... the cath lab. Patient demographics, ... images and procedural information all flow ... record, eliminating repetitive data entry. ...
The flexible EXXCEL ePTFE Vascular Access Graft material is designed to offer textile-like handling characteristics-cuts neatly for a clean edge, retains fully open lumen shape, and sutures smoothly....
Data Trol™ Normal Control Serum provides the laboratory with vital information on the performance of clinical chemistry assays in the Normal range....
... Data Trol™ Abnormal Control Serum is intended for ... clinical chemistry assays. It is for in vitro ... 5ml lyophilized format, the control offers up to ... reconstituted. The control is to be used in ...
Medicine Products: